Equities

Hamlet BioPharma AB

Hamlet BioPharma AB

Actions
  • Price (SEK)3.60
  • Today's Change0.16 / 4.65%
  • Shares traded81.17k
  • 1 Year change+52.09%
  • Beta1.2247
Data delayed at least 15 minutes, as of Sep 13 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Jun 30 2024202420232022
ASSETS
Cash And Short Term Investments231840
Total Receivables, Net3.730.490.85
Total Inventory------
Prepaid expenses0.470.131.27
Other current assets, total------
Total current assets271942
Property, plant & equipment, net0.5700
Goodwill, net------
Intangibles, net419.48--
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets692842
LIABILITIES
Accounts payable1.230.131.72
Accrued expenses2.402.131.82
Notes payable/short-term debt--00
Current portion long-term debt/capital leases--00
Other current liabilities, total0.480.280.17
Total current liabilities4.112.553.72
Total long term debt05.000
Total debt05.000
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities4.117.553.72
SHAREHOLDERS EQUITY
Common stock1.681.121.11
Additional paid-in capital225141137
Retained earnings (accumulated deficit)(163)(121)(100)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity642138
Total liabilities & shareholders' equity692842
Total common shares outstanding168115113
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.